Sagent Pharm Inc (SGNT) 15.50 $SGNT
Athenex Announces the Addition of James Hussey to Lead its Commercial Business Activities
PR Newswire - Fri Jul 08, 8:00AM CDT
Athenex, Inc. announced today that James Hussey has joined the Company as Executive Vice President of Athenex Pharmaceutical Division. In this capacity, Mr. Hussey will be responsible for the execution of the commercial aspects of this business unit including strategy, new products, manufacturing, distribution, sales and marketing.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 240.59 (+2.58), SGNT: 15.50 (-0.55), TEVA: 50.89 (+0.37)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter
GlobeNewswire - Mon Jun 13, 4:52PM CDT
Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10g (NDC 25021-163-69) Lot OXT515 (Exp. Date July 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent. Sagent has initiated this voluntary recall of Oxacillin for Injection, USP, 10g to the user level due to the receipt of two product complaints for small, dark particulate matter found in solution after reconstitution. The presence of particulate matter during administration has the potential to cause adverse health consequences in general patient populations.
SGNT: 15.50 (-0.55)
Sagent reports 1Q loss
Automated Insights - Tue May 03, 6:52AM CDT
SCHAUMBURG, Ill. (AP) _ Sagent Pharmaceuticals Inc. (SGNT) on Tuesday reported a loss of $5 million in its first quarter.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:30AM CDT
Company Affirms 2016 Full Year Guidance
SGNT: 15.50 (-0.55)
Athenex Announces Jeffrey Yordon to Lead Newly Formed Specialty Products Division
PR Newswire - Tue Apr 26, 7:00AM CDT
Athenex, Inc. announced today that Jeffrey Yordon has joined the Company as President of the newly formed subsidiary, Athenex Specialty Products. In this capacity, Mr. Yordon will be responsible for all aspects of the business unit including strategy, new products, manufacturing, distribution, sales and marketing.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 8:07AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, today announced that it will release financial results for the 2016 first quarter pre-market on Tuesday, May 3, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 15.50 (-0.55)
Stock Picking Strategy to Win Every Earnings Season
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 5:27PM CDT
We are running a great screen which will help you get into winning stocks ahead of every earnings season.
CPN: 14.51 (+0.28), INGN: 51.91 (-0.49), SGNT: 15.50 (-0.55), MTN: 140.23 (+0.63), PFSW: 9.41 (+0.15)
Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development
GlobeNewswire - Wed Mar 23, 3:05PM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Sean Brynjelsen as Executive Vice President, Business Development. In this newly created role, Mr. Brynjelsen will develop and execute a strategy to drive long-term growth through the acceleration of product licensing, acquisition of products and portfolios as well as the execution of other M&A activity. Mr. Brynjelsen will report directly to Allan Oberman, Sagent's Chief Executive Officer.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Wed Feb 03, 3:00PM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 fourth quarter and full year pre-market on Tuesday, February 16, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 15.50 (-0.55)
Why Sagent Pharmaceuticals Inc. Jumped Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Jan 13, 2:53PM CST
What: Sagent Pharmaceuticals surged this morning and was up as much as 19% today after Reuters reported that the company has hired an investment bank to solicit bids to buy the generic-drug maker. So what: Reuters appears to have multiple...
PFE: 36.12 (+0.35), SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO(R) (Lidocaine HCl Jelly USP, 2%)
GlobeNewswire - Tue Jan 12, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) announced its GLYDO(R) (lidocaine HCl jelly USP, 2%) has received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association, and Provista. The designation was based on reviews of GLYDO by hospital experts who attended Novation's Innovative Technology Expo in November. The annual event provides medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to organization's care and business models.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals to Present at 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Fri Jan 08, 11:55AM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 34 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 2:00 p.m. PT (4:00 p.m. CT/5:00 p.m. ET). The presentation is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website, www.sagentpharma.com. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
JPM: 61.83 (+1.25), SGNT: 15.50 (-0.55)
Timing is Crucial, Upside Analysis - Analyst Notes on Sagent Pharmaceuticals, Del Frisco's Restaurant Group, Air Transport Services Group and Edge Therapeutics
ACCESSWIRE - Thu Dec 24, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / December 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), Del Frisco's Restaurant Group Inc. (NASDAQ: DFRG), Air Transport Services Group Inc. (NASDAQ: ATSG) and Edge Therapeutics Inc. (NASDAQ: EDGE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DFRG: 14.60 (+0.18), ATSG: 13.19 (+0.34), SGNT: 15.50 (-0.55), EDGE: 9.73 (-0.14)
Healthcare Sector Equities in Motion -- Tetraphase Pharma, Cardiovascular Systems, Sagent Pharma, and GenMark Diagnostics
ACCESSWIRE - Mon Dec 21, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Cardiovascular Systems Inc. (NASDAQ: CSII), Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), and GenMark Diagnostics Inc. (NASDAQ: GNMK). Free research report on Tetraphase Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GNMK: 9.98 (+0.10), TTPH: 4.49 (+0.11), CSII: 19.62 (+1.12), SGNT: 15.50 (-0.55)
Global Antibacterial Drugs Market 2015-2019
M2 - Fri Dec 04, 4:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/nm7f8c/global) has announced the addition of the "Global Antibacterial Drugs Market 2015-2019" report to their offering. The report forecasts the global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019. The report presents scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Antibacterial Overview PART 06: Pipeline analysis PART 07: Antimicrobial resistance PART 08: Legislation relating to antibiotic use in the US PART 09: Market landscape PART 10: Market segmentation by chemical class PART 11: Market segmentation by drug origin PART 12: Market segmentation by mechanism of action PART 13: Market segmentation by spectrum of activity PART 14: Geographical segmentation PART 15: Market drivers PART 16: Impact of drivers PART 17: Market challenges PART 18: Impact of drivers and challenges PART 19: Market trends PART 20: Vendor landscape PART 21: Key vendor analysis - Allergan - GSK - Merck - Pfizer - Sandoz - Teva Pharmaceuticals - Abbott - Achaogen - Actelion - AmpliPhi Biosciences - Aspen Pharmacare - Astellas - AstraZeneca - Aurobindo Pharma - Baxter - Basilea Pharmaceuticals - Bayer - Biocon - Bristol-Myers Squibb - Cempra - Cipher Pharmaceuticals - Corden Pharma - Cornerstone Therapeutics - Eli Lilly - Exoxemis - F.Hoffmann-La Roche - Flynn Pharma - Hospira - Incepta Pharmaceuticals - InSite Vision - Insmed Incorporated - Johnson & Johnson - KaloBios Pharmaceuticals - Kyorin Pharmaceutical - Lupin Pharmaceuticals - Lytix Biopharma - Melinta Therapeutics - Mylan - Nektar - Orchid Pharma - Par Pharmaceutical - Paratek Pharmaceuticals - Pernix Therapeutics - PTC Therapeutics - RedHill Biopharma - Sagent Pharmaceuticals - Sanofi - Shionogi - Starpharma - Sun Pharmaceutical - Symbiomix - Takeda Pharma - Tetraphase Pharmaceuticals - Theravance Biopharma - The Medicines Company - Valneva - Wockhardt. For more information visit http://www.researchandmarkets.com/research/nm7f8c/global
TTPH: 4.49 (+0.11), INSM: 10.75 (+0.33), RDHL: 11.30 (+0.35), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), PRTK: 13.29 (-0.12), APHB: 1.58 (+0.01), AGN: 240.59 (+2.58), JNJ: 122.85 (+0.34), MRK: 59.35 (+0.57), SGNT: 15.50 (-0.55), PTCT: 7.53 (+0.02), TBPH: 23.46 (+0.46)
Equities on the Move - Research on Sagent Pharmaceuticals, Alliance Fiber Optic Products, Dicerna Pharmaceuticals and Addus Homecare
ACCESSWIRE - Wed Nov 18, 7:10AM CST
NEW YORK, NY / ACCESSWIRE/ November 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), Alliance Fiber Optic Products Inc. (NASDAQ: AFOP), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) and Addus Homecare Corp. (NASDAQ: ADUS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DRNA: 3.48 (-0.06), AFOP: 18.51 (+0.01), ADUS: 19.00 (+0.46), SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 03, 6:00AM CST
Company Affirms 2015 Full Year Guidance
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals unveils Chlorothiazide Sodium for Injection, USP in patients with edema
M2 - Wed Oct 28, 5:49AM CDT
Pharmaceutical company Sagent Pharmaceuticals (NasdaqGS:SGNT) reported on Tuesday the availability of its diuretic/antihypertensive agent, Chlorothiazide Sodium for Injection USP, in a 500 mg preservative-free, single-dose vial.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Announces the Launch of Chlorothiazide Sodium for Injection, USP
GlobeNewswire - Tue Oct 27, 3:08PM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) today announced the launch of Chlorothiazide Sodium for Injection, USP, a diuretic/antihypertensive agent, in a 500 mg preservative-free, single-dose vial. According to IMS, for the 12 months ending August 2015, the US market for Chlorothiazide approximated $29 million. As with all products in Sagent's portfolio, Chlorothiazide features Sagent's PreventIV Measures Packaging and Labeling, designed to help reduce the risk of medication errors.
SGNT: 15.50 (-0.55)
Athenex Announces the Addition of James Hussey to Lead its Commercial Business Activities
PR Newswire - Fri Jul 08, 8:00AM CDT
Athenex, Inc. announced today that James Hussey has joined the Company as Executive Vice President of Athenex Pharmaceutical Division. In this capacity, Mr. Hussey will be responsible for the execution of the commercial aspects of this business unit including strategy, new products, manufacturing, distribution, sales and marketing.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd.
GlobeNewswire - Thu Jun 16, 7:00AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered into a definitive agreement with Teva Pharmaceutical Industries Ltd. (Teva) and Actavis LLC to acquire a portfolio of five Abbreviated New Drug Applications (ANDAs) in the U.S. for $40 million. The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business.
AGN: 240.59 (+2.58), SGNT: 15.50 (-0.55), TEVA: 50.89 (+0.37)
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter
GlobeNewswire - Mon Jun 13, 4:52PM CDT
Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10g (NDC 25021-163-69) Lot OXT515 (Exp. Date July 2017) manufactured by Astral SteriTech Private Limited and distributed by Sagent. Sagent has initiated this voluntary recall of Oxacillin for Injection, USP, 10g to the user level due to the receipt of two product complaints for small, dark particulate matter found in solution after reconstitution. The presence of particulate matter during administration has the potential to cause adverse health consequences in general patient populations.
SGNT: 15.50 (-0.55)
Sagent reports 1Q loss
Automated Insights - Tue May 03, 6:52AM CDT
SCHAUMBURG, Ill. (AP) _ Sagent Pharmaceuticals Inc. (SGNT) on Tuesday reported a loss of $5 million in its first quarter.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 03, 6:30AM CDT
Company Affirms 2016 Full Year Guidance
SGNT: 15.50 (-0.55)
Athenex Announces Jeffrey Yordon to Lead Newly Formed Specialty Products Division
PR Newswire - Tue Apr 26, 7:00AM CDT
Athenex, Inc. announced today that Jeffrey Yordon has joined the Company as President of the newly formed subsidiary, Athenex Specialty Products. In this capacity, Mr. Yordon will be responsible for all aspects of the business unit including strategy, new products, manufacturing, distribution, sales and marketing.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2016 Financial Results
GlobeNewswire - Mon Apr 25, 8:07AM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, today announced that it will release financial results for the 2016 first quarter pre-market on Tuesday, May 3, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 15.50 (-0.55)
Stock Picking Strategy to Win Every Earnings Season
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 5:27PM CDT
We are running a great screen which will help you get into winning stocks ahead of every earnings season.
CPN: 14.51 (+0.28), INGN: 51.91 (-0.49), SGNT: 15.50 (-0.55), MTN: 140.23 (+0.63), PFSW: 9.41 (+0.15)
Sagent Pharmaceuticals Names Sean Brynjelsen Executive Vice President, Business Development
GlobeNewswire - Wed Mar 23, 3:05PM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Sean Brynjelsen as Executive Vice President, Business Development. In this newly created role, Mr. Brynjelsen will develop and execute a strategy to drive long-term growth through the acceleration of product licensing, acquisition of products and portfolios as well as the execution of other M&A activity. Mr. Brynjelsen will report directly to Allan Oberman, Sagent's Chief Executive Officer.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Sets Date and Time for Release of Fourth Quarter and Full Year 2015 Financial Results
GlobeNewswire - Wed Feb 03, 3:00PM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 fourth quarter and full year pre-market on Tuesday, February 16, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
SGNT: 15.50 (-0.55)
Why Sagent Pharmaceuticals Inc. Jumped Today
Brian Orelli, The Motley Fool - Motley Fool - Wed Jan 13, 2:53PM CST
What: Sagent Pharmaceuticals surged this morning and was up as much as 19% today after Reuters reported that the company has hired an investment bank to solicit bids to buy the generic-drug maker. So what: Reuters appears to have multiple...
PFE: 36.12 (+0.35), SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Receives Innovative Technology Designation From Novation for GLYDO(R) (Lidocaine HCl Jelly USP, 2%)
GlobeNewswire - Tue Jan 12, 7:00AM CST
Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) announced its GLYDO(R) (lidocaine HCl jelly USP, 2%) has received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association, and Provista. The designation was based on reviews of GLYDO by hospital experts who attended Novation's Innovative Technology Expo in November. The annual event provides medical technology suppliers the opportunity to demonstrate their product and gain direct feedback from onsite clinical experts and health care providers on the impact their products may have on improving clinical care, safety, or benefits to organization's care and business models.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals to Present at 34th Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Fri Jan 08, 11:55AM CST
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that it will present at the 34 Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 2:00 p.m. PT (4:00 p.m. CT/5:00 p.m. ET). The presentation is being webcast and can be accessed on the "Events and Presentations" page of the "Investor Relations" section of the Company's website, www.sagentpharma.com. In order to register and download any necessary software, please log on 10 minutes prior to the start of the webcast.
JPM: 61.83 (+1.25), SGNT: 15.50 (-0.55)
Timing is Crucial, Upside Analysis - Analyst Notes on Sagent Pharmaceuticals, Del Frisco's Restaurant Group, Air Transport Services Group and Edge Therapeutics
ACCESSWIRE - Thu Dec 24, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / December 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), Del Frisco's Restaurant Group Inc. (NASDAQ: DFRG), Air Transport Services Group Inc. (NASDAQ: ATSG) and Edge Therapeutics Inc. (NASDAQ: EDGE). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DFRG: 14.60 (+0.18), ATSG: 13.19 (+0.34), SGNT: 15.50 (-0.55), EDGE: 9.73 (-0.14)
Healthcare Sector Equities in Motion -- Tetraphase Pharma, Cardiovascular Systems, Sagent Pharma, and GenMark Diagnostics
ACCESSWIRE - Mon Dec 21, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / December 21, 2015 / Park Lane Advisor has initiated coverage on the following equities: Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH), Cardiovascular Systems Inc. (NASDAQ: CSII), Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), and GenMark Diagnostics Inc. (NASDAQ: GNMK). Free research report on Tetraphase Pharma can be accessed at http://www.parklaneadvisor.com/ On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%. The losses were broad based as all the sectors ended the session in negative. Register for your complimentary reports at the links given below.
GNMK: 9.98 (+0.10), TTPH: 4.49 (+0.11), CSII: 19.62 (+1.12), SGNT: 15.50 (-0.55)
Global Antibacterial Drugs Market 2015-2019
M2 - Fri Dec 04, 4:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/nm7f8c/global) has announced the addition of the "Global Antibacterial Drugs Market 2015-2019" report to their offering. The report forecasts the global antibacterial drugs market to grow at a CAGR of 1.06% over the period 2014-2019. The report presents scenario and growth prospects of the global antibacterial drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria. The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global antibacterial drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Antibacterial Overview PART 06: Pipeline analysis PART 07: Antimicrobial resistance PART 08: Legislation relating to antibiotic use in the US PART 09: Market landscape PART 10: Market segmentation by chemical class PART 11: Market segmentation by drug origin PART 12: Market segmentation by mechanism of action PART 13: Market segmentation by spectrum of activity PART 14: Geographical segmentation PART 15: Market drivers PART 16: Impact of drivers PART 17: Market challenges PART 18: Impact of drivers and challenges PART 19: Market trends PART 20: Vendor landscape PART 21: Key vendor analysis - Allergan - GSK - Merck - Pfizer - Sandoz - Teva Pharmaceuticals - Abbott - Achaogen - Actelion - AmpliPhi Biosciences - Aspen Pharmacare - Astellas - AstraZeneca - Aurobindo Pharma - Baxter - Basilea Pharmaceuticals - Bayer - Biocon - Bristol-Myers Squibb - Cempra - Cipher Pharmaceuticals - Corden Pharma - Cornerstone Therapeutics - Eli Lilly - Exoxemis - F.Hoffmann-La Roche - Flynn Pharma - Hospira - Incepta Pharmaceuticals - InSite Vision - Insmed Incorporated - Johnson & Johnson - KaloBios Pharmaceuticals - Kyorin Pharmaceutical - Lupin Pharmaceuticals - Lytix Biopharma - Melinta Therapeutics - Mylan - Nektar - Orchid Pharma - Par Pharmaceutical - Paratek Pharmaceuticals - Pernix Therapeutics - PTC Therapeutics - RedHill Biopharma - Sagent Pharmaceuticals - Sanofi - Shionogi - Starpharma - Sun Pharmaceutical - Symbiomix - Takeda Pharma - Tetraphase Pharmaceuticals - Theravance Biopharma - The Medicines Company - Valneva - Wockhardt. For more information visit http://www.researchandmarkets.com/research/nm7f8c/global
TTPH: 4.49 (+0.11), INSM: 10.75 (+0.33), RDHL: 11.30 (+0.35), LLY: 79.66 (+0.34), BMY: 75.28 (+1.20), PRTK: 13.29 (-0.12), APHB: 1.58 (+0.01), AGN: 240.59 (+2.58), JNJ: 122.85 (+0.34), MRK: 59.35 (+0.57), SGNT: 15.50 (-0.55), PTCT: 7.53 (+0.02), TBPH: 23.46 (+0.46)
Equities on the Move - Research on Sagent Pharmaceuticals, Alliance Fiber Optic Products, Dicerna Pharmaceuticals and Addus Homecare
ACCESSWIRE - Wed Nov 18, 7:10AM CST
NEW YORK, NY / ACCESSWIRE/ November 18, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Sagent Pharmaceuticals Inc. (NASDAQ: SGNT), Alliance Fiber Optic Products Inc. (NASDAQ: AFOP), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) and Addus Homecare Corp. (NASDAQ: ADUS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
DRNA: 3.48 (-0.06), AFOP: 18.51 (+0.01), ADUS: 19.00 (+0.46), SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Reports Third Quarter 2015 Financial Results
GlobeNewswire - Tue Nov 03, 6:00AM CST
Company Affirms 2015 Full Year Guidance
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals unveils Chlorothiazide Sodium for Injection, USP in patients with edema
M2 - Wed Oct 28, 5:49AM CDT
Pharmaceutical company Sagent Pharmaceuticals (NasdaqGS:SGNT) reported on Tuesday the availability of its diuretic/antihypertensive agent, Chlorothiazide Sodium for Injection USP, in a 500 mg preservative-free, single-dose vial.
SGNT: 15.50 (-0.55)
Sagent Pharmaceuticals Announces the Launch of Chlorothiazide Sodium for Injection, USP
GlobeNewswire - Tue Oct 27, 3:08PM CDT
Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) today announced the launch of Chlorothiazide Sodium for Injection, USP, a diuretic/antihypertensive agent, in a 500 mg preservative-free, single-dose vial. According to IMS, for the 12 months ending August 2015, the US market for Chlorothiazide approximated $29 million. As with all products in Sagent's portfolio, Chlorothiazide features Sagent's PreventIV Measures Packaging and Labeling, designed to help reduce the risk of medication errors.
SGNT: 15.50 (-0.55)
